LLY logo Eli Lilly and Company +
Eli Lilly and Company
+

Eli Lilly and Company (LLY) Business News

Track Eli Lilly and Company in real time with a live news feed covering Eli Lilly and Company stock news, official press releases, company announcements, and an archive of historical Eli Lilly and Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:45 AM | Wednesday | Nov 11, 2026 PRNewsWire

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

News Thumbnail
6:47 AM | Friday | Nov 6, 2026 PRNewsWire

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

News Thumbnail
6:45 AM | Thursday | Nov 5, 2026 PRNewsWire

Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

News Thumbnail
6:45 AM | Thursday | Oct 29, 2026 PRNewsWire

Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

News Thumbnail
11:19 AM | Monday | Oct 26, 2026 PRNewsWire

Lilly declares fourth-quarter 2026 dividend

News Thumbnail
2:30 AM | Saturday | Oct 24, 2026 PRNewsWire

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

News Thumbnail
10:30 AM | Thursday | Oct 22, 2026 PRNewsWire

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

News Thumbnail
4:40 AM | Monday | Oct 19, 2026 PRNewsWire

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

News Thumbnail
10:00 AM | Thursday | Oct 15, 2026 PRNewsWire

Lilly confirms date and conference call for third-quarter 2026 financial results announcement

News Thumbnail
8:00 AM | Thursday | Oct 15, 2026 PRNewsWire

New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year

News Thumbnail

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

PRNewsWire

9:45 AM | Wednesday | Nov 11, 2026

news photo
Loading...

Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improvements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpoint Detailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology  INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition.

Read full article redirect
9:45 AM | Wednesday | Nov 11, 2026

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

PRNewsWire

Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improvements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpoint Detailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology  INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with... Read more

Read full article arrow
News Thumbnail
6:47 AM | Friday | Nov 6, 2026

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

PRNewsWire

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Nov 5, 2026

Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

PRNewsWire

Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials Detailed Phase 3b TOGETHER-PsA data showed positive results across disease activity, patient-reported and metabolic outcomes at one year for Taltz and Zepbound vs. Taltz alone in adults with psoriatic arthritis and obesity INDIANAPOLIS, Nov. 5, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new clinical and real-world research in people with knee osteoarthritis pain and obesity and those with psoriatic arthritis and obesity at the American College of Rheumatology (ACR) Convergence 2026, taking place Nov. 6-11 in Orlando.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Oct 29, 2026

Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

PRNewsWire

Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount estimates.

Read full article arrow
News Thumbnail
11:19 AM | Monday | Oct 26, 2026

Lilly declares fourth-quarter 2026 dividend

PRNewsWire

INDIANAPOLIS, Oct. 26, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on December 10, 2026, to shareholders of record at the close of business on November 13, 2026.

Read full article arrow
News Thumbnail
2:30 AM | Saturday | Oct 24, 2026

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

PRNewsWire

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive... Read more

Read full article arrow
News Thumbnail
10:30 AM | Thursday | Oct 22, 2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

PRNewsWire

First Lilly site to produce both active pharmaceutical ingredients and finished medicines in a fully integrated facility Site will create 650 high-wage jobs INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company's more than $50 billion push to expand medicine production in the U.
S., the Richmond site will be Lilly's first to produce both API and finished medicines in a fully integrated facility, with dedicated API capacity for bioconjugate and large-molecule medicines.

Read full article arrow
News Thumbnail
4:40 AM | Monday | Oct 19, 2026

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

PRNewsWire

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis More than 80% of patients responded to Omvoh induction, and half of responders, ages 6 to 17, were in clinical remission at one year in Phase 3 SHINE-2 study In key secondary outcomes, 71.2% of patients who responded to Omvoh induction achieved symptomatic remission and 50% achieved corticosteroid-free clinical remission at one year without surgery INDIANAPOLIS, Oct. 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis (UC), including clinical, symptomatic and endoscopic... Read more

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Oct 15, 2026

Lilly confirms date and conference call for third-quarter 2026 financial results announcement

PRNewsWire

INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Oct 15, 2026

New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year

PRNewsWire

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use In VIVID-1, one in five (20.4%) Omvoh-treated patients with Crohn's disease achieved corticosteroid-free deep remission, a composite outcome defined by simultaneous clinical remission, endoscopic remission and no corticosteroid use   Across both types of inflammatory bowel disease, including patients with prior biologic failure, achieving comprehensive disease control or corticosteroid-free deep remission was associated with improved patient-reported outcomes INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- New data analyses from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease treated with Omvoh (mirikizumab-mrkz) achieved multiple treatment goals simultaneously at... Read more

Read full article arrow
News Thumbnail